m6A-mRNA reader YTHDF2 identified as a potential risk gene in autism with disproportionate megalencephaly - Nishizaki, Sierra S.; Haghani, Nicholas K.; La, Gabriana N.; Mariano, Natasha Ann F.; Uribe-Salazar, José M.; Kaya, Gulhan; Regester, Melissa; Andrews, Derek Sayre; Nordahl, Christine Wu; Amaral, David G.; Dennis, Megan Y. (medRxiv, 2024)
Among autistic individuals, a subphenotype of disproportionate megalencephaly (ASD-DM) seen at three years of age is associated with co-occurring intellectual disability and poorer prognoses later in life. However, many of the genes contributing to ASD-DM have yet to be delineated. In this study, we identified additional ASD-DM candidate genes with the aim to better define the genetic etiology of this subphenotype of autism. We expanded the previously studied sample size of ASD-DM individuals ten-fold by including probands from the Autism Phenome Project and Simons Simplex Collection, totaling 766 autistic individuals meeting the criteria for megalencephaly or macrocephaly and revealing 153 candidate ASD-DM genes harboring de novo protein-impacting variants. Our findings include thirteen high confidence autism genes and seven genes previously associated with DM. Five impacted genes have previously been associated with both autism and DM, including CHD8 and PTEN. By performing functional network analysis, we expanded to additional candidate genes, including one previously implicated in ASD-DM (PIK3CA) as well as 184 additional genes previously implicated in ASD or DM alone. Using zebrafish as a model, we performed CRISPR gene editing to generate knockout animals for seven of the genes and assessed head-size and induced-seizure-activity differences. From this analysis, we identified significant morphological changes in zebrafish loss-of-function of two genes, ythdf2 and ryr3. While zebrafish knockouts model haploinsufficiency of assayed genes, we identified a de novo tandem duplication impacting YTHDF2 in an ASD-DM proband. Testing zebrafish overexpressing YTHDF2 showed increased head and brain size matching that of the proband. Single-cell transcriptomes of YTHDF2 gain-of-function larvae point to reduced expression of Fragile-X-syndrome-associated FMRP-target genes globally and in the developing brain, providing insight into the mechanism underlying autistic phenotypes. We additionally discovered a variant impacting a different m6A-methylation reader, YTHDC1, in our ASD-DM cohort. Though we highlight only two cases to date, our study provides support for the m6A-RNA methylation pathway as potentially contributing to this severe form of autism.Lay Summary Autism (ASD) has become increasingly prevalent in children in recent years due to increasing awareness and improving diagnosis. While we know ASD is associated with hundreds of genes, there is much to learn about what genes are involved and how they contribute to its diverse presentation of traits and behaviors. By focusing on autistic individuals exhibiting enlarged brains (disproportionate megalencephaly), we identified new candidate genes possibly contributing to ASD and brain size. A autistic-patient-identified duplication of one gene in particular, YTHDF2, implicates a novel pathway related to RNA modifications with ASD and human brain size for the first time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by a pilot grant from the UC Davis MIND Institute Intellectual and Developmental Disabilities Research Center funded by NIH National Institute of Child Health and Human Development (P50HD103526), the NIH National Institute of Neurological Disorder and Stroke (R21NS128811), and the NIH Office of the Director and National Institute of Mental Health (DP2MH119424) to MYD. SSN is supported by the NIMH Autism Research Training Program T32 (MH073124) through the UC Davis MIND Institute; NAFM is supported by the NIGMS as a UC Davis Postbaccalaureate Research Education Program fellow (R25GM116690); GNL is supported by an NINDS Research Supplement to Promote Diversity in Health-Related Research (R21NS128811-01A1W1); NKH is supported by an NIGMS UC Davis eMCDB T32 (T32GM153586).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yes